Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Sponsor: Regeneron Pharmaceuticals

Expanded Access

Sponsor score: 60

Inactive

ClinicalTrials ID:NCT05164250

This program facilitates Compassionate Use of REGN5458 for patients with relapsed or refractory multiple myeloma through Individual Patient IND applications. REGN5458 is the investigational drug provided under this initiative. Eligibility criteria are not specified, focusing solely on individual patient requests.

Patient Parameters

Parameter	Options

Program Overview

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.